Anti-Cancer Agents and Biological Therapy
Clinical Pharmacology of Anti-Cancer Agents
Oncological Emergencies
Latest ESMO videos
Featured medwireNews
Thoracic Cancer Mortality After COVID-19 Not Linked To Recent Systemic Therapy
Pembrolizumab–Etoposide Offers Long-Term ‘Clinically Meaningful Improvement’ In ES-SCLC Survival
Durvalumab Biliary Tract Cancer Benefit Observed Regardless Of Primary Tumour Location
BRCAness Phenotype May Predict Intraphepatic Cholangiocarcinoma Response To Treatment
T-DXd Shows ‘Promising Activity’ For HER2-Positive, Advanced Biliary Tract Cancer
E-Learning
ESMO E-Learning: PARP Inhibitors: Past, Present and Future
ESMO E-Learning: Cardiotoxicity in Oncology Practice
ESMO E-Learning: Multimodular Treatment in Head and Neck Squamous Cell Carcinoma (HNSCC)
ESMO V-Learning: BRCA Across Tumour Types
ESMO E-Learning: Management of Cancer Associated Thrombosis
Meeting resources
Participants Clinical Case Discussion: Toxicity management of first-line Pembrolizumab combined with Axitinib in metastatic clear cell RCC
Presenter: D. Spanu, IT
Session: Session 8 - Side Effects Management
Resources:
Slides
Webcast
Participants Clinical Case Discussion: Complete response of mRCC following successful management of immune related toxicities
Presenter: C. Markellos, GR
Session: Session 8 - Side Effects Management
Resources:
Slides
Webcast
Participants Clinical Case Discussion: Metastatic bladder cancer: a one-of-a-kind case report
Presenter: D. Silva, PT
Session: Session 8 - Side Effects Management
Resources:
Slides
Webcast
IO/IO and IO single agent
Presenter: C. Porta, IT
Session: Session 8 - Side Effects Management
Resources:
Slides
Webcast
IO-VEGFR TKI
Presenter: G. Von Amsberg, DE
Session: Session 8 - Side Effects Management
Resources:
Slides
Webcast